News

October 25, 2018
14 years strong: Northern California patient support group
On October 20th the Northern California Amyloidosis Support Group celebrated it’s fourteenth year with a meeting held at Stanford’s Blake Wilbur Cancer Center. (more…)
Read More

October 5, 2018
Tegsedi (Inotersen) approved by FDA for hATTR amyloidosis
The U.S. Food and Drug Administration today approved Tegsedi (inotersen), a novel therapy for the treatment of hereditary TTR amyloidosis polyneuropathy. (more…)
Read More

September 25, 2018
Cardiac Amyloid takes center stage at HFSA
For many years, cardiac amyloid has had a few remarkable champions, preaching to half-empty rooms at medical conferences. Well, all that has changed. (more…)
Read More

August 24, 2018
ARC CEO Named 2018 Rare Champion of Hope
Earlier this month, ARC CEO, Isabelle Lousada was among a small group of honorees named 2018 RARE Champion of Hope award recipients by Global Genes. (more…)
Read More

August 10, 2018
FDA approves first treatment for hereditary ATTR amyloidosis
The U.S. Food and Drug Administration today approved Patisiran, a novel therapy for the treatment of hereditary ATTR amyloidosis polyneuropathy. (more…)
Read More
- Categories
- Archives
- February 2019 (1)
- January 2019 (1)
- December 2018 (3)
- October 2018 (2)
- September 2018 (1)
- August 2018 (2)
- July 2018 (2)
- April 2018 (3)
- March 2018 (2)
- February 2018 (3)
- January 2018 (2)
- December 2017 (4)
- November 2017 (2)
- October 2017 (1)
- August 2017 (1)
- July 2017 (1)
- June 2017 (1)
- April 2017 (1)
- February 2017 (1)
- December 2016 (2)
- October 2016 (2)
- September 2016 (1)
- July 2016 (4)
- June 2016 (4)
- May 2016 (1)
- April 2016 (2)
- March 2016 (1)
- February 2016 (2)
- December 2015 (1)
- November 2015 (3)
- October 2015 (1)
- September 2015 (1) More